Pulling for a Cure: Lessons Learned with John Lambert
Over the past four decades, John Lambert has spent most of his time either on the water or in the lab. Today, Lambert is Executive VP Emeritus & Distinguished Research Fellow at ImmunoGen, and a Director of the Head Of The Charles Regatta. Here, he talks antibody-drug conjugates and his involvement with Kadcyla.
James Strachan |
In 1632, some 700 Puritan colonists made the long journey from England to Massachusetts. Their leaders were University of Cambridge alumni looking for opportunities in a far-away land – and they called their new settlement “Cambridge” after the ancient University. John Lambert’s career has taken a similar (though less perilous) path – beginning at Christ’s College Cambridge in the UK in 1969 and still going strong in Cambridge, Massachusetts, on the banks of the Charles River.
And though Lambert says he can’t claim a history quite as exciting as those original colonists who sailed out for the New World (but he’s probably spent more time on the water given his love of rowing!), he has been able to watch – and help – the antibody-drug conjugate (ADC) field develop from a concept into real therapies. Here, Lambert shares his lessons learned.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.